Comparison of the immunostimulatory and proinflammatory activities of candidate Gram-positive endotoxins, lipoteichoic acid, peptidoglycan, and lipopeptides, in murine and human cells.
The role of lipopolysaccharide (LPS) in the pathogenesis of Gram-negative septic shock is well established. The corresponding proinflammatory and immunostimulatory molecule(s) on the Gram-positive bacteria is less well understood, and its identification and characterization would be a key prerequisite in designing specific sequestrants of the Gram-positive endotoxin(s). We report in this paper the comparison of NF-kappaB-, cytokine- and chemokine-inducing activities of the TLR2 ligands, lipoteichoic acid (LTA), peptidoglycan (PGN), and lipopeptides, to LPS, a prototype TLR4 agonist, in murine macrophage cell-lines as well as in human blood. In murine cells, di- and triacyl liopopeptides are equipotent in their NF-kappaB inducing activity relative to LPS, but elicit much lower proinflammatory cytokines. However, both LPS and the lipopeptides potently induce the secretion of a pattern of chemokines that is suggestive of the engagement of a TLR4-independent TRIF pathway. In human blood, although the lipopeptides induce p38 MAP kinase phosphorylation and CD11b upregulation in granulocytes at ng/ml concentrations, they do not elicit proinflammatory cytokine production even at very high doses; LTA, however, activates neutrophils and induces cytokine secretion, although its potency is considerably lower than that of LPS, presumably due to its binding to plasma proteins. We conclude that, in human blood, the pattern of immunostimulation and proinflammatory mediator production elicited by LTA parallels that of LPS.
Kimbrell
Matthew R
MR
Department of Medicinal Chemistry, University of Kansas, United States.
Warshakoon
Hemamali
H
Cromer
Jens R
JR
Malladi
Subbalakshmi
S
Hood
Jennifer D
JD
Balakrishna
Rajalakshmi
R
Scholdberg
Tandace A
TA
David
Sunil A
SA
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D001773:Blood Cells / Q000187:drug effects; D002460:Cell Line; D002477:Cells / Q000187:drug effects*; D004731:Endotoxins / Q000276:immunology / Q000494:pharmacology*; D006094:Gram-Positive Bacteria / Q000737:chemistry; D006801:Humans; D007249:Inflammation / Q000139:chemically induced* / Q000276:immunology; D008070:Lipopolysaccharides / Q000276:immunology / Q000494:pharmacology*; D008074:Lipoproteins / Q000276:immunology / Q000494:pharmacology*; D008264:Macrophages / Q000166:cytology / Q000187:drug effects; D051379:Mice; D010457:Peptidoglycan / Q000276:immunology / Q000494:pharmacology*; D013682:Teichoic Acids / Q000276:immunology / Q000494:pharmacology*; D051195:Toll-Like Receptor 2 / Q000819:agonists / Q000097:blood / Q000378:metabolism
D000276:Adjuvants, Immunologic; D004731:Endotoxins; D008070:Lipopolysaccharides; D008074:Lipoproteins; D010457:Peptidoglycan; D013682:Teichoic Acids; D051195:Toll-Like Receptor 2; C009900:lipoteichoic acid